title: Successful therapeutic effect in a mouse model of erythropoietic protoporphyria by partial genetic correction and fluorescence-based selection of hematopoietic cells.
abstract: Erythropoietic protoporphyria is characterized clinically by skin photosensitivity and biochemically by a ferrochelatase deficiency resulting in an excessive accumulation of photoreactive protoporphyrin in erythrocytes, plasma and other organs. The availability of the Fech(m1Pas)/Fech(m1Pas) murine model allowed us to test a gene therapy protocol to correct the porphyric phenotype. Gene therapy was performed by ex vivo transfer of human ferrochelatase cDNA with a retroviral vector to deficient hematopoietic cells, followed by re-injection of the transduced cells with or without selection in the porphyric mouse. Genetically corrected cells were separated by FACS from deficient ones by the absence of fluorescence when illuminated under ultraviolet light. Five months after transplantation, the number of fluorescent erythrocytes decreased from 61% (EPP mice) to 19% for EPP mice engrafted with low fluorescent selected BM cells. Absence of skin photosensitivity was observed in mice with less than 20% of fluorescent RBC. A partial phenotypic correction was found for animals with 20 to 40% of fluorescent RBC. In conclusion, a partial correction of bone marrow cells is sufficient to reverse the porphyric phenotype and restore normal hematopoiesis. This selection system represents a rapid and efficient procedure and an excellent alternative to the use of potentially harmful gene markers in retroviral vectors.
authors.affiliation: Laboratoire de Pathologie Moléculaire et Thérapie Génique, Université Victor Segalen Bordeaux 2, France.
authors.forename: A
authors.initials: A
authors.lastname: Fontanellas
authors.forename: M
authors.initials: M
authors.lastname: Mendez
authors.forename: F
authors.initials: F
authors.lastname: Mazurier
authors.forename: M
authors.initials: M
authors.lastname: Cario-André
authors.forename: S
authors.initials: S
authors.lastname: Navarro
authors.forename: C
authors.initials: C
authors.lastname: Ged
authors.forename: L
authors.initials: L
authors.lastname: Taine
authors.forename: F
authors.initials: F
authors.lastname: Géronimi
authors.forename: E
authors.initials: E
authors.lastname: Richard
authors.forename: F
authors.initials: F
authors.lastname: Moreau-Gaudry
authors.forename: R
authors.initials: R
authors.lastname: Enriquez De Salamanca
authors.forename: H
authors.initials: H
authors.lastname: de Verneuil
mesh_terms: D000818:Animals; D002460:Cell Line; D002469:Cell Separation / Q000379:methods*; D018076:DNA, Complementary / Q000235:genetics; D004195:Disease Models, Animal; D005260:Female; D005294:Ferrochelatase / Q000235:genetics; D005434:Flow Cytometry; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D007377:Interleukin-3 / Q000502:physiology; D008107:Liver Diseases / Q000628:therapy; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010641:Phenotype; D010787:Photosensitivity Disorders / Q000628:therapy; D017121:Porphyria, Hepatoerythropoietic / Q000503:physiopathology / Q000628:therapy*; D012190:Retroviridae / Q000235:genetics
chemical_list: D018076:DNA, Complementary; D007377:Interleukin-3; D005294:Ferrochelatase